May 08, 2026 06:53 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Cloud over Tamil Nadu government formation as Governor asks Vijay to prove majority | 1 Year of Operation Sindoor: PM Modi says it showed India’s firm response to terror | ‘Larger conspiracy ahead of PM Modi’s visit’: BJP on killing of Suvendu Adhikari’s aide | ‘My car was on OLX for sale’: Siliguri owner says number plate used in Suvendu aide assassination may have been cloned online | ‘Pre-planned political assassination’: BJP’s Swapan Dasgupta on Suvendu aide’s killing | BJP leader Suvendu Adhikari's personal secretary shot dead in West Bengal's Madhyamgram | Mamata Banerjee to move Supreme Court against Bengal post-poll violence, refuses to quit | Who after Mamata in Bengal? Amit Shah to meet BJP MLA-elects ahead of May 9 oath | Vijay’s TVK seeks Congress, Left support after falling short of majority in Tamil Nadu | Jolt to TMC! Supreme Court rejects plea challenging central staff deployment at Bengal counting centres
Johnson&Johnson Vaccine

Kolkata's Peerless Hospital commences Johnson & Johnson vaccine's clinical trial

| @indiablooms | May 08, 2021, at 03:50 am

Kolkata/IBNS: Kolkata's Peerless Hospital has been selected as the only trial venue in the East for Johnson & Johnson for their single-dose vaccine which is currently being used under emergency authorization.

In a statement Dr Subhrajyoti Bhowmick, Clinical trial specialist and clinical Pharmacologist and Director, Clinical Research Peerless Hospital, Kolkata said, " We shall be recruiting 100 participants at this site, six such sites have been selected for this trial of this unique single dose vaccine."

"I am confident we shall get enough volunteers for the clinical trial as vaccine supply is short and the supply of Covishield and Covaxine is less than the huge demand. The ratio shall be 3:1 as three volunteers will get a vaccine while one person shall get a placebo. We are now awaiting the ethics committee approval on which we shall embark on the clinical trials," concluded Bhowmick.

Earlier, Sputnik V, developed by Gamaleya Research Institute of Epidemiology and Microbiology in Russia, has been approved for use in India.

Five million doses of Sputnik V are expected to arrive in India by June.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.